Advertisement

The Indian Journal of Pediatrics

, Volume 78, Issue 7, pp 826–832 | Cite as

Transient Myeloproliferative Disorder and GATA1 Mutation in Neonates With and Without Down Syndrome

  • Ming-Horng Tsai
  • Jia-Woei Hou
  • Chao-Ping YangEmail author
  • Pong-Hong Yang
  • Shih-Ming Chu
  • Jen-Fu Hsu
  • Ming-Chou Chiang
  • Hsuan-Rong Huang
Original Article

Abstract

Objective

To report clinical experiences and cytogenetic findings of transient myeloproliferative disorder (TMD) in neonates with and without Down syndrome (DS).

Methods

GATA1 gene was screened in DNA samples from neonates presenting with TMD during their leukemic and remission status.

Results

Six neonates (2 phenotypically normal and 4 DS) born in the past 6 years had presented with TMD; all had trisomy 21 during leukemic status. Two DS infants died during early infancy, one of hepatic failure and one of cardiac complication. One non-DS infant evolved into myelodysplastic syndrome (MDS) and acute leukemia since 14 months old. Three other patients have not developed true leukemia after follow-up of 8, 9, and 70 months, respectively. The authors detected mutations within exon 2 of GATA1 gene in 3 DS and 2 non-DS infants. All these mutations disappeared after remission of TMD, but an identical mutation was detected in one non-DS patient when evolving into MDS. Trisomy 21 was confined to leukemic clone in non-DS patients.

Conclusions

TMD should be considered in case of congenital leukemia with megakaryoblastic features and accompanied by trisomy 21 and GATA1 mutation. Both DS and non-DS patients will possibly develop true leukemia within few years.

Keywords

Transient myeloproliferative disorder Down syndrome GATA1 mutation Acute megakaryoblastic leukemia Trisomy 21 

Notes

Contributions MHT; design and write this article, CPY; the corresponding author, JWH; responsible for all cytogenetic and all other five co-authors were major physicians of these patients during neonatal periods.

Conflict of Interest

None.

Role of Funding Source

None.

References

  1. 1.
    Massey GV. Transient leukemia in newborns with Down syndrome. Pediatr Blood Cancer. 2005;44:29–32.PubMedCrossRefGoogle Scholar
  2. 2.
    Schunk GJ, Lehman WL. Mongolism and congenital leukemia. JAMA. 1954;155:250–1.Google Scholar
  3. 3.
    Engel R, Hammond D. Transient congenital leukemia in 7 infants with mongolism. J Pediatr. 1964;65:303–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Magalhães IQ, Splendore A, Emerenciano M, et al. Transient neonatal myeloproliferative disorder without Down syndrome and detection of GATA1 mutation. J Pediatr Hematol Oncol. 2005;27:50–2.PubMedCrossRefGoogle Scholar
  5. 5.
    Cushing T, Clericuzio CL, Wilson CS, et al. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder. J Pediatr. 2006;148:687–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Brissette MD, Duval-Arnould BJ, Gordon BG, Cotelingam JD. Acute megakaryoblastic leukemia following transient myeloproliferative disorder in a patient without Down syndrome. Am J Hematol. 1994;47:316–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Richards M, Welch J, Watmore A, Readett D, Vora AJ. Trisomy 21 associated transient neonatal myeloproliferation in the absence of Down’s syndrome. Arch Dis Child Fetal Neonatal Ed. 1998;79:F215–217.PubMedCrossRefGoogle Scholar
  8. 8.
    Crispino JD. GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia. Pediatr Blood Cancer. 2005;44:40–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Gassas A, Doyle JJ, Weitzman S, et al. A basic classification and a comprehensive pediatric myeloproliferative disorder. J Pediatr Hematol Oncol. 2005;27:192–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Massey GV, Zipursky A, Chang MN, et al. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): a Children’s Oncology Group (COG) study POG-9481. Blood. 2006;107:4606–13.PubMedCrossRefGoogle Scholar
  11. 11.
    Vyas P, Crispino JD. Molecular insights into Down syndrome-associated leukemia. Curr Opin Pediatr. 2007;19:9–14.PubMedCrossRefGoogle Scholar
  12. 12.
    Greene ME, Mundschau G, Wechsler J, et al. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome. Blood Cells Mol Dis. 2003;31:351–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Ahmed M, Sternberg A, Hall G, et al. Natural history of GATA1 mutations in Down syndrome. Blood. 2004;103:2480–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Zipursky A, Brown EJ, Christensen H, Doyle J. Transient myeloproliferative disorder (transient leukemia) and hematologic manifestations of Down syndrome. Clin Lab Med. 1999;19:157–67.PubMedGoogle Scholar
  15. 15.
    Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukemia and solid tumors in individuals with Down’s syndrome. Lancet. 2000;355:165–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Massey GV. Transient leukemia in newborns with Down syndrome. Pediatr Blood Cancer. 2005;44:29–32.PubMedCrossRefGoogle Scholar
  17. 17.
    Brink DS. Transient leukemia (transient myeloproliferative disorder, transient abnormal myelopoiesis) of Down syndrome. Adv Anat Pathol. 2006;13:256–62.PubMedCrossRefGoogle Scholar
  18. 18.
    Zipursky A, Brown E, Christensen H, Sutherland R, Doyle J. Leukemia and/or myeloproliferative syndrome in neonates with Down syndrome. Semin Perinatol. 1997;21:97–101.PubMedCrossRefGoogle Scholar
  19. 19.
    Adam M, Vincenot A, Gouraud F, et al. Transient myeloproliferative disorder in a neonate without Down syndrome. Ann Biol Clin (Paris). 2007;65:569–73.Google Scholar
  20. 20.
    Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32:148–52.PubMedCrossRefGoogle Scholar
  21. 21.
    Li Z, Godinho FJ, Klusmann JH, Garriga-Canut M, Yu C, Orkin SH. Developmental stage selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet. 2005;37:613–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Muntean AG, Crispino JD. Differential requirements for the activation domain and FOG-interaction surface of GATA-1 in megakaryocyte gene expression and development. Blood. 2005;106:1223–31.PubMedCrossRefGoogle Scholar
  23. 23.
    Carpenter E, Valverde-Garduno V, Sternberg A, Mitchell C, Roberts I, Vyas R. GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder. Br J Haematol. 2005;128:548–51.PubMedCrossRefGoogle Scholar
  24. 24.
    Gurbuxani S, Vyas P, Crispino JD. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood. 2004;103:399–406.PubMedCrossRefGoogle Scholar
  25. 25.
    Xu G, Kato K, Toki T, Yoshihiro T, Kiminori T, Ito E. Development of acute megakaryoblastic leukemia from a minor clone in a Down syndrome patient with clinically overt transient myeloproliferative disorder. J Pediatr Hematol Oncol. 2006;28:696–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Chou ST, Opalinska JB, Yao Y, et al. Trisomy 21 enhances human fetal erythro-megakaryocytic development. Blood. 2008;112:4503–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Stark B, Jeison M, Preudhomme C, et al. Acquired trisomy 21 and distinct clonal evolution in acute megakaryoblastic leukaemia in young monozygotic twins. Br J Haematol. 2002;118:1082–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Rainis L, Bercovich D, Strehl S, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood. 2003;102:981–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Pine SR, Guo Q, Yin C, Jayabose S, Druschel CM, Sandoval C. Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. Blood. 2007;110:2128–31.PubMedCrossRefGoogle Scholar
  30. 30.
    Shin MG, Choi HW, Kim HR, et al. Tetrasomy 21 as a sole acquired abnormality without GATA1 gene mutation in pediatric acute megakaryoblastic leukemia: a case report and review of the literature. Leuk Res. 2008;32:1615–9.PubMedCrossRefGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2011

Authors and Affiliations

  • Ming-Horng Tsai
    • 1
    • 4
    • 5
  • Jia-Woei Hou
    • 3
    • 5
  • Chao-Ping Yang
    • 1
    • 5
    Email author
  • Pong-Hong Yang
    • 2
    • 5
  • Shih-Ming Chu
    • 2
    • 5
  • Jen-Fu Hsu
    • 2
    • 5
  • Ming-Chou Chiang
    • 2
    • 5
  • Hsuan-Rong Huang
    • 2
    • 5
  1. 1.Division of Pediatric Hematology/Oncology, Department of PediatricsChang Gung Memorial HospitalTaoyuanTaiwan
  2. 2.Division of Pediatric Neonatology, Department of PediatricsChang Gung Memorial HospitalTaoyuanTaiwan
  3. 3.Division of Medical Genetics, Department of PediatricsChang Gung Memorial HospitalTaoyuanTaiwan
  4. 4.Division of Neonatology and Pediatric Hematology/Oncology, Department of PediatricsChang Gung Memorial HospitalYunlinTaiwan
  5. 5.Chang Gung University School of MedicineTaoyuanTaiwan

Personalised recommendations